NEWTOWN SQUARE, Pa., April 15, 2014 /PRNewswire/ -- Kibow Biotech is pleased to participate in the Buzz of BIO for the 2014 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 23-26, 2014 at the San Diego Convention Center in California. During the Buzz of BIO contest, industry leaders as well as the general public will be voting for companies they want to see at the event's BIO Business Forum. Voting will take place online from April 15 through April 22 at http://convention.bio.org/buzzofbio/voting.aspx.

Logo - http://photos.prnewswire.com/prnh/20140414/73029
Logo - http://photos.prnewswire.com/prnh/20140414/73030

This is the first time that a biotechnology business company exclusively specializing on dietary supplement products is being recognized as one of the selected and nominated among 40 U.S. companies for the "Pipeline of Promise or Technologies of Tomorrow" category.  Dr. Natarajan Ranganathan – the co-founder and chief R&D scientist says that "the decade of research efforts on the concept of balancing the gut microbiome with probiotics (beneficial health impacting microbes) is finally gaining more recognition". He also added that a scientific basis and rationale for "a shift from human genome to gut microbiome" has been established only recently, and the process of using it to address various healthcare problems is just beginning.

Kibow's management believes that despite being a dietary supplement company, Kibow was selected because of the scientific and drug-like validation of its patented, proprietary probiotic product for maintaining healthy kidney function. Kibow is best known for its veterinary (Azodyl®) and human (Renadyl™) products for individuals with kidney failure problems. 

The company's nomination is a cumulative impact of its earlier selection for a poster presentation as Emerging Biotech Company at the BIO-Boston meeting, its novel concept, and its pharmaceutical-like validation of the product based on "enteric uremic toxin reduction technology" (Enteric Dialysis®).  This dietary supplement product, in combination with the standard-of-care treatment for primary diseases such as diabetes, hypertension and other related conditions, may help delay the progression to dialysis status. Subject to additional clinical trials and its validation, the product also possesses an excellent potential to reduce the frequency or duration of dialysis, affording better outcomes and saving billions of healthcare dollars worldwide.   Kibow and its R&D team have also developed a proprietary blend of prebiotics for multitargeted wellness application and is looking for partnering with a major INTERNATIONAL pharmaceutical or Biotech Company.  (continued)

ABOUT THE BIO INTERNATIONAL CONVENTION

The largest, most influential biotech meeting in the world is coming to the San Diego Convention Center, June 23-26, 2014, offering four days of career-boosting opportunities that you won't find anywhere else—from sessions and specialty forums covering 17 hot topics to networking events, 1,700+ exhibitors and BIO One-on-One Partnering meetings with thousands of companies.  Join the global biotech community in San Diego and discover where BIO 2014 can take you. Register now at convention.bio.org.

ABOUT KIBOW BIOTECH INC: 

About Kibow Biotech: Founded in Oct 1, 1997 in Philadelphia, Kibow Biotech specializes in research, development and commercialization of probiotic dietary supplements adhering to US FDA and FTC regulations. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health and other healthcare applications. The Company's flagship product, Renadyl™, is currently marketed in the U.S. and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.

About Enteric Uremic Toxin Reduction Technology:

Kibow's novel "enteric uremic toxin reduction technology" addresses the accumulation of various uremic toxins which diffuse into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for humans) and Azodyl® (veterinary formulation) consist of a combination of three specific probiotic microbial strains. The results of various clinical trials, including the latest conducted in 2012, have provided encouraging preliminary evidence that the Company's technology could be effective when the product formulation is taken regularly according to medical directives and in a context of standard care as dictated by individual conditions.

Forward-looking statements:  This press release contains forward-looking statements that reflect management's current views of future events, including the current status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug or food supplement in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a prevention product or therapy. The dietary supplement formulation of Renadyl™ will not cure, prevent or mitigate any disease. Other factors that could cause or contribute to differences in actual results include, but are not limited to, risks associated with any future clinical trials of product candidates, the possibility that testing may reveal to be undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Contact:

Mary Galambert
KIBOW BIOTECH INC
610-353-5130 ext. 225
WWW.KIBOWBIOTECH.COM

Read more news from Kibow Biotech Inc.

SOURCE Kibow Biotech